1. Travis, W. D., Brambilla, E., Muller-Hermelink, H. K., & Harris, C. C. (2004). Pathology and Genetics of Tumours of the Lung, Pleura, Thymus, and Heart, World Health Organization Classification of Tumours. Lyon: IARC.
2. Nicholson, A. G., Gonzalez, D., Shah, P., Pynegar, M. J., Deshmukh, M., Rice, A., et al. (2010). Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of Mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. Journal of Thoracic Oncology, 5, 436–441.
3. Peto, R., Lopez, A. D., Boreham, J., Thun, M., & Heath, C, Jr. (1994). Mortality from smoking in developed countries 1950–2000 (Vol. 143, p. 658). Indirect Estimates from National Vital Statistics: Oxford University Press, New York.
4. Sridhar, S. S., Seymour, L., & Shepherd, F. A. (2003). Inhibitors of epidermal-growth-factor receptors: A review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncology, 4, 397–406.
5. Sawyers, C. L. (2002). Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell, 1, 413–415.